If you have metastatic non-small-cell lung cancer (NSCLC), you might wonder if the treatment plan that your doctor recommended is the best one for you. Metastatic NSCLC is “stage IV” or ...

The first patient has been dosed in the phase 3 TACTI-004 trial evaluating efti with Keytruda and chemotherapy for advanced ...

Key Phase III Trials in NSCLC : Ivonescimab monotherapy vs ... improving and contributing to the global IO cancer treatment landscape. Breakthrough Bispecifics Enter NRDL, Paving the Way for ...

First patient safely dosed at Calvary Mater Newcastle Hospital in Australia, marking a significant milestone for ImmutepGlobal Phase III with ...

Living with stage 4 NSCLC can feel scary. However, encouraging treatment developments are helping people live longer and enjoy a better quality of life. A 2020 research review even states that new ...

In April 2025, Amgen announced a study is to evaluate the safety, tolerability, and to determine the maximum tolerated dose ...

Once a mutation is identified, a doctor may modify your cancer treatment to target it. A genetic mutation in the lungs can cause non-small cell lung cancer (NSCLC). Different mutations can affect ...

Final overall survival results show amivantamab plus lazertinib beat out osimertinib for first-line treatment of advanced ...

Global first "immuno + anti-vascular" bispecific antibody approved: ivonescimab for EGFR-TKI resistant nsq-NSCLC. Phase III ... with AK117 for first-line HNSCC treatment, compared with pembrolizumab.

On the commercial front, Akeso's adjustments in drug pricing and optimization of its commercial systems led to new drug sales revenue surpassing RMB 2 billion in 2024, a 25% year-on-year increase. The ...

This positions Akeso as a key innovator in next-generation cancer immunotherapy, improving and contributing to the global IO cancer treatment landscape ... locally advanced or metastatic non-squamous ...